Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study

The Lancet Neurology

Volumn 8, Issue 11, 2009, Pages 998-1005

  Urbanus, Rolf T ^a   Siegerink, Bob ^b   Roest, Mark ^a   Rosendaal, Frits R ^b   de Groot, Philip G ^a   Algra, Ale ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; PROTHROMBIN ANTIBODY; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; ADOLESCENT; BLOOD; BRAIN ISCHEMIA; CLINICAL TRIAL; DIABETES MELLITUS; GENETICS; HYPERLIPIDEMIA; MIDDLE AGED; MULTICENTER STUDY; RISK ASSESSMENT; SMOKING; STROKE; THROMBOSIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; DIABETES MELLITUS; FACTOR V; FACTOR XIII; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNOGLOBULIN G; LUPUS COAGULATION INHIBITOR; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT; SMOKING; STROKE; THROMBOSIS; YOUNG ADULT;

EID: 70449729881     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70239-X     Document Type: Article

References (35)

1. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 (2002) 1019-1027
2. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
3. Galli M., Luciani D., Bertolini G., and Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003) 1827-1832
4. Brey R.L., Stallworth C.L., McGlasson D.L., et al. Antiphospholipid antibodies and stroke in young women. Stroke 33 (2002) 2396-2400
5. Meroni P.L., Peyvandi F., Foco L., et al. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 5 (2007) 2421-2428
6. Metz L.M., Edworthy S., Mydlarski R., and Fritzler M.J. The frequency of phospholipid antibodies in an unselected stroke population. Can J Neurol Sci 25 (1998) 64-69
7. Runchey S.S., Folsom A.R., Tsai M.Y., Cushman M., and McGovern P.D. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 119 (2002) 1005-1010
8. Vaarala O., Manttari M., Manninen V., et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91 (1995) 23-27
9. Vaarala O., Puurunen M., Manttari M., et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 75 (1996) 456-459
10. Janardhan V., Wolf P.A., Kase C.S., et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 35 (2004) 736-741
11. Galli M., Reber G., de Moerloose P., and de Groot P.G. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 6 (2008) 399-401
12. Kemmeren J.M., Tanis B.C., van den Bosch M.A., et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 33 (2002) 1202-1208
13. Tanis B.C., van den Bosch M.A., Kemmeren J.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345 (2001) 1787-1793
14. Rosendaal F.R., Siscovick D.S., Schwartz S.M., et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89 (1997) 2817-2821
15. Longstreth Jr. W.T., Rosendaal F.R., Siscovick D.S., et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 29 (1998) 577-580
16. Rosendaal F.R., Siscovick D.S., Schwartz S.M., et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 90 (1997) 1747-1750
17. De Stefano V., Chiusolo P., Paciaroni K., et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 91 (1998) 3562-3565
18. Pruissen D.M., Slooter A.J., Rosendaal F.R., van der Graaf Y., and Algra A. Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 111 (2008) 1282-1286
19. Slooter A.J., Rosendaal F.R., Tanis B.C., et al. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 3 (2005) 1213-1217
20. Horbach D.A., van Oort E., Donders R.C., Derksen R.H., and de Groot P.G. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 76 (1996) 916-924
21. de Laat H.B., Derksen R.H., Urbanus R.T., Roest M., and de Groot P.G. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104 (2004) 3598-3602
22. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
23. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
24. Cole P., and MacMahon B. Attributable risk percent in case-control studies. Brit J Prev Soc Med 25 (1971) 242-244
25. Anderson R.E., Pfeffer M.A., Thune J.J., et al. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Am Heart J 155 (2008) 706-711
26. Sarti C., Stegmayr B., Tolonen H., et al. Are changes in mortality from stroke caused by changes in stroke event rates or case fatality? Results from the WHO MONICA Project. Stroke 34 (2003) 1833-1840
27. Camerlingo M., Casto L., Censori B., et al. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand 92 (1995) 69-71
28. Thiagarajan P., Pengo V., and Shapiro S.S. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 68 (1986) 869-874
29. Urbanus R.T., Derksen R.H., and de Groot P.G. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Rev 22 (2008) 93-105
30. Safa O., Esmon C.T., and Esmon N.L. Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies. Blood 106 (2005) 1629-1635
31. Ambrose J.A., and Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43 (2004) 1731-1737
32. Rosing J., Middeldorp S., Curvers J., et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 354 (1999) 2036-2040
33. de Groot P.G., Lutters B., Derksen R.H., et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 3 (2005) 1993-1997
34. Rothwell P.M. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366 (2005) 1773-1783
35. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133 (2008) 630S-669S